COMPASS Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Its focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. It is pioneering the development of a new model of psilocybin therapy, in which its proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and it is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. It is headquartered in London, UK, with offices in New York, USA. Its vision is a world of mental wellbeing.